Effect of high versus standard protein provision on functional recovery in people with critical illness (PRECISe): an investigator-initiated, double-blinded, multicentre, parallel-group, randomised controlled trial in Belgium and the Netherlands
Julia L M Bels,Steven Thiessen,Rob J J van Gassel,Albertus Beishuizen,Ashley De Bie Dekker,Vincent Fraipont,Stoffel Lamote,Didier Ledoux,Clarissa Scheeren,Elisabeth De Waele,Arthur R H van Zanten,Laura Bormans-Russell,Bas C T van Bussel,Marlies M J Dictus,Tom Fivez,Ingeborg Harks,Iwan C C van der Horst,Joop Jonckheer,Hugues Marechal,Paul B Massion,Ingrid Meex,Michelle C Paulus,Martin Rinket,Susanne van Santen,Katrien Tartaglia,Adam M Deane,Frieda Demuydt,Zudin Puthucheary,Lilian C M Vloet,Peter J M Weijs,Sander M J van Kuijk,Marcel C G van de Poll,Dieter Mesotten,PRECISe study team,Julia Lm Bels,Bas Ct van Bussel,Rob Jj van Gassel,Iwan Cc van der Horst,Sander Mj van Kuijk,Marcel Cg van de Poll,Danielle van den Berk,Esther van den Hogen,Laure-Anne van Loon,Luc Jc van Loon,Marlies Mj Dictus,Tom Fiez,Willem Boer,Kim Engelen,Margot Vander Laenen,Xavier Willaert,Joy Demol,Janne Geers,Marie-Claire van Malderen,Godelieve Opdenacker,Chloë Verhelst,Arthur Rh van Zanten,Marianne Bouw-Ruiter,Imre Kouw,Max Melchers,Margreet Osinga,Yvonne Swaen-Dekkers,Alexander D Cornet,Tim Krol,Wytze Vermeijden,Meta van der Woude,Eric Zandijk,Sofie Lagast,Isabel Boscart,Paul Massion,Lilian Vloet,Peter Mj Weijs,Adam Deane
DOI: https://doi.org/10.1016/S0140-6736(24)01304-7
2024-08-17
Abstract:Background: Increased protein provision might ameliorate muscle wasting and improve long-term outcomes in critically ill patients. The aim of the PRECISe trial was to assess whether higher enteral protein provision (ie, 2·0 g/kg per day) would improve health-related quality of life and functional outcomes in critically ill patients who were mechanically ventilated compared with standard enteral protein provision (ie, 1·3 g/kg per day). Methods: The PRECISe trial was an investigator-initiated, double-blinded, multicentre, parallel-group, randomised controlled trial in five Dutch hospitals and five Belgian hospitals. Inclusion criteria were initiation of invasive mechanical ventilation within 24 h of intensive care unit (ICU) admission and an expected duration of invasive ventilation of 3 days or longer. Exclusion criteria were contraindications for enteral nutrition, moribund condition, BMI less than 18 kg/m2, kidney failure with a no dialysis code, or hepatic encephalopathy. Patients were randomly assigned to one of four randomisation labels, corresponding with two study groups (ie, standard or high protein; two labels per group) in a 1:1:1:1 ratio through an interactive web-response system. Randomisation was done via random permuted-block randomisation in varying block sizes of eight and 12, stratified by centre. Participants, care providers, investigators, outcome assessors, data analysts, and the independent data safety monitoring board were all blinded to group allocation. Patients received isocaloric enteral feeds that contained 1·3 kcal/mL and 0·06 g of protein/mL (ie, standard protein) or 1·3 kcal/mL and 0·10 g of protein/mL (ie, high protein). The study-nutrition intervention was limited to the time period during the patient's ICU stay in which they required enteral feeding, with a maximum of 90 days. The primary outcome was EuroQoL 5-Dimension 5-level (EQ-5D-5L) health utility score at 30 days, 90 days, and 180 days after randomisation, adjusted for baseline EQ-5D-5L health utility score. This trial was registered with ClinicalTrials.gov (NCT04633421) and is closed to new participants. Findings: Between Nov 19, 2020, and April 14, 2023, 935 patients were randomly assigned. 335 (35·8%) of 935 patients were female and 600 (64·2%) were male. 465 (49·7%) of 935 were assigned to the standard protein group and 470 (50·3%) were assigned to the high protein group. 430 (92·5%) of 465 patients in the standard protein group and 419 (89·1%) of 470 patients in the high protein group were assessed for the primary outcome. The primary outcome, EQ-5D-5L health utility score during 180 days after randomisation (assessed at 30 days, 90 days, and 180 days), was lower in patients allocated to the high protein group than in those allocated to the standard protein group, with a mean difference of -0·05 (95% CI -0·10 to -0·01; p=0·031). Regarding safety outcomes, the probability of mortality during the entire follow-up was 0·38 (SE 0·02) in the standard protein group and 0·42 (0·02) in the high protein group (hazard ratio 1·14, 95% CI 0·92 to 1·40; p=0·22). There was a higher incidence of symptoms of gastrointestinal intolerance in patients in the high protein group (odds ratio 1·76, 95% CI 1·06 to 2·92; p=0·030). Incidence of other adverse events did not differ between groups. Interpretation: High enteral protein provision compared with standard enteral protein provision resulted in worse health-related quality of life in critically ill patients and did not improve functional outcomes during 180 days after ICU admission. Funding: Netherlands Organisation for Healthcare Research and Development and Belgian Health Care Knowledge Centre.